
WASHINGTON D.C. — U.S. Sens. Martin Heinrich, D-N.M., and Ben Ray Luján, D-N.M., alongside 17 of their Senate colleagues, urged the U.S. Food and Drug Administration Commissioner to rely on scientific evidence and data as the FDA considers approval of MDMA-Assisted Therapy to treat Post-Traumatic Stress Disorder in a letter dated Aug. 5. MDMA-AT could help address the mental and behavioral crisis, especially among American veterans.
“Existing treatments and medicines for PTSD, the last of which FDA approved nearly 25 years ago, have not decreased the frequency of suicide within the veteran community. As a nation, we cannot allow our veterans to continue to suffer in silence and...